Literature DB >> 26801398

Characterization of the Discriminative Stimulus Effects of a NOP Receptor Agonist Ro 64-6198 in Rhesus Monkeys.

Phillip A Saccone1, Kathy A Zelenock2, Angela M Lindsey2, Agnieszka Sulima2, Kenner C Rice2, Eric P Prinssen2, Jürgen Wichmann2, James H Woods2.   

Abstract

Nociceptin/orphanin FQ receptor (NOP) agonists have been reported to produce antinociceptive effects in rhesus monkeys with comparable efficacy to μ-opioid receptor (MOP) agonists, but without their limiting side effects. There are also known to be species differences between rodents and nonhuman primates (NHPs) in the behavioral effects of NOP agonists. The aims of this study were the following: 1) to determine if the NOP agonist Ro 64-6198 could be trained as a discriminative stimulus; 2) to evaluate its pharmacological selectivity as a discriminative stimulus; and 3) to establish the order of potency with which Ro 64-6198 produces discriminative stimulus effects compared with analgesic effects in NHPs. Two groups of rhesus monkeys were trained to discriminate either fentanyl or Ro 64-6198 from vehicle. Four monkeys were trained in the warm-water tail-withdrawal procedure to measure antinociception. Ro 64-6198 produced discriminative stimulus effects that were blocked by the NOP antagonist J-113397 and not by naltrexone. The discriminative stimulus effects of Ro 64-6198 partially generalized to diazepam, but not to fentanyl, SNC 80, ketocyclazocine, buprenorphine, phencyclidine, or chlorpromazine. Fentanyl produced stimulus effects that were blocked by naltrexone and not by J-113397, and Ro 64-6198 did not produce fentanyl-appropriate responding in fentanyl-trained animals. In measures of antinociception, fentanyl, but not Ro 64-6198, produced dose-dependent increases in tail-withdrawal latency. Together, these results demonstrate that Ro 64-6198 produced stimulus effects in monkeys that are distinct from other opioid receptor agonists, but may be somewhat similar to diazepam. In contrast to previous findings, Ro 64-6198 did not produce antinociception in the majority of animals tested even at doses considerably greater than those that produced discriminative stimulus effects. U.S. Government work not protected by U.S. copyright.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26801398      PMCID: PMC4809320          DOI: 10.1124/jpet.115.231134

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  29 in total

1.  Influence of the selective ORL1 receptor agonist, Ro64-6198, on rodent neurological function.

Authors:  G A Higgins; A J Grottick; T M Ballard; J G Richards; J Messer; H Takeshima; M Pauly-Evers; F Jenck; G Adam; J Wichmann
Journal:  Neuropharmacology       Date:  2001-07       Impact factor: 5.250

2.  Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception.

Authors:  Glenn W Stevenson; John E Folk; David C Linsenmayer; Kenner C Rice; S Stevens Negus
Journal:  J Pharmacol Exp Ther       Date:  2003-10-13       Impact factor: 4.030

3.  Discriminative stimulus effects of the nonpeptidic delta-opioid agonist SNC80 in rhesus monkeys.

Authors:  M R Brandt; S S Negus; N K Mello; M S Furness; X Zhang; K C Rice
Journal:  J Pharmacol Exp Ther       Date:  1999-09       Impact factor: 4.030

Review 4.  Discriminative and analgesic effects of mu and kappa opioids: in vivo pA2 analysis.

Authors:  L A Dykstra; A J Bertalmio; J H Woods
Journal:  Psychopharmacol Ser       Date:  1988

5.  Pharmacological analysis of the discriminative stimulus characteristics of ethylketazocine in the rhesus monkey.

Authors:  D W Hein; A M Young; S Herling; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1981-07       Impact factor: 4.030

6.  Discriminative stimulus properties of clozapine and chlorpromazine.

Authors:  J A Goas; J E Boston
Journal:  Pharmacol Biochem Behav       Date:  1978-03       Impact factor: 3.533

Review 7.  The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family.

Authors:  J S Mogil; G W Pasternak
Journal:  Pharmacol Rev       Date:  2001-09       Impact factor: 25.468

8.  A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat.

Authors:  F Jenck; J Wichmann; F M Dautzenberg; J L Moreau; A M Ouagazzal; J R Martin; K Lundstrom; A M Cesura; S M Poli; S Roever; S Kolczewski; G Adam; G Kilpatrick
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

9.  Discriminative stimulus effects of N-substituted analogs of phencyclidine in rhesus monkeys.

Authors:  R E Solomon; S Herling; E F Domino; J H Woods
Journal:  Neuropharmacology       Date:  1982-12       Impact factor: 5.250

10.  The opioid receptor like-1 receptor agonist Ro 64-6198 (1S,3aS-8-2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one) produces a discriminative stimulus in rats distinct from that of a mu, kappa, and delta opioid receptor agonist cue.

Authors:  Matthew D Recker; Guy A Higgins
Journal:  J Pharmacol Exp Ther       Date:  2004-06-29       Impact factor: 4.030

View more
  5 in total

Review 1.  Utility of Nonhuman Primates in Substance Use Disorders Research.

Authors:  Matthew L Banks; Paul W Czoty; Sidney S Negus
Journal:  ILAR J       Date:  2017-12-01

2.  Lack of effect of the nociceptin opioid peptide agonist Ro 64-6198 on pain-depressed behavior and heroin choice in rats.

Authors:  Megan Jo Moerke; S Stevens Negus; Matthew L Banks
Journal:  Drug Alcohol Depend       Date:  2021-12-30       Impact factor: 4.492

3.  Analysis of the distribution of spinal NOP receptors in a chronic pain model using NOP-eGFP knock-in mice.

Authors:  Akihiko Ozawa; Gloria Brunori; Andrea Cippitelli; Nicholas Toll; Jennifer Schoch; Brigitte L Kieffer; Lawrence Toll
Journal:  Br J Pharmacol       Date:  2018-05-06       Impact factor: 8.739

Review 4.  The NOP Receptor System in Neurological and Psychiatric Disorders: Discrepancies, Peculiarities and Clinical Progress in Developing Targeted Therapies.

Authors:  Lawrence Toll; Andrea Cippitelli; Akihiko Ozawa
Journal:  CNS Drugs       Date:  2021-05-31       Impact factor: 6.497

5.  Synthesis, Biological Evaluation, and SAR Studies of 14β-phenylacetyl Substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones Derivatives: Ligands With Mixed NOP and Opioid Receptor Profile.

Authors:  Vinod Kumar; Willma E Polgar; Gerta Cami-Kobeci; Mark P Thomas; Taline V Khroyan; Lawrence Toll; Stephen M Husbands
Journal:  Front Psychiatry       Date:  2018-09-19       Impact factor: 4.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.